Trial Profile
A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Garadacimab (Primary) ; Garadacimab (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Sponsors CSL Behring
- 02 Nov 2021 Status changed from active, no longer recruiting to completed.
- 01 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2020 Results (n=32) presented in a CSL Behring Media Release.